BFM
GYRE icon

Boothbay Fund Management’s Gyre Therapeutics GYRE Stock Holding History

Boothbay Fund Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-21
Closed -$402K – 803
2018
Q1 		$402K Buy
+21
New +$3.92K 0.05% 384

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Boothbay Fund Management's GYRE Position: Q2 2022 in Review

Boothbay Fund Management sold out of Gyre Therapeutics (GYRE) in Q2 2022, closing a stake of 6,122 shares — an estimated $30K sold.

Boothbay Fund Management first reported a position in GYRE in Q1 2018 and held it in 8 quarters. The position peaked at $667K in Q2 2018. 41 funds tracked by Wall St. Rank hold GYRE as of Q2 2022.

  • Boothbay Fund Management reported no remaining Gyre Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 6,122 Gyre Therapeutics shares in Q2 2022, an estimated $30K.
  • Boothbay Fund Management first reported a position in Gyre Therapeutics in Q1 2018 and held it in 8 quarters.
  • Boothbay Fund Management's Gyre Therapeutics position peaked at $667K in Q2 2018.
  • 41 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2022.

Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.